Liraglutide (3mg)
Liraglutide is an approved GLP-1 agonist (Victoza®/Saxenda®) for T2D and weight management. Half-life of ~13 hours—administered daily.
Reviewed by the AllPeptides.eu Editorial Team·Last reviewed: 2026-06-16
Educational information. Not medical advice, and no efficacy claim is implied. Regulatory approval is not a use recommendation by AllPeptides.eu.
⚠️ For informational/educational purposes only. Not medical advice. We do not sell any products. Self-treatment carries serious risks — consult a healthcare professional. Disclaimer
Research monograph
See the full Liraglutide encyclopedia page with mechanism, evidence tier, related variants and research context.
How It Works
Liraglutide mimics GLP-1, enhancing glucose-dependent insulin, suppressing glucagon, slowing gastric emptying, and reducing appetite. It differs from semaglutide in its half-life (~13 hours vs ~7 days).
Quick Start
- Reconstitution: Add 1.0 mL bacteriostatic water → 3.0 mg/mL concentration.
- Daily range: 0.6–3.0 mg once daily.
- Storage: 2–8 °C.
Titration Schedule (1 mL = 3.0 mg/mL)
Route: Subcutaneously | Frequency: Once daily
| Week | Dose | Units (per injection) |
|---|---|---|
| Week 1 | 0.6 mg | 20 Units (0.20 mL) |
| Week 2 | 1.2 mg | 40 Units (0.40 mL) |
| Week 3 | 1.8 mg | 60 Units (0.60 mL) |
| Week 4 | 2.4 mg | 80 Units (0.80 mL) |
| Week 5+ | 3.0 mg | 100 Units (1.00 mL) |
Studies report administration once daily at any time. Increase by +0.6 mg each week.
Related compounds
Reconstitution Steps
- Withdraw 1.0 mL bacteriostatic water.
- Inject slowly.
- Gently swirl.
- Refrigerate at 2–8 °C.
Protocol Overview
- Objective: Weight loss or glycemic control.
- Schedule: Daily, long-term use.
- Half-life: ~13 hours (vs ~7 days for semaglutide).
Dosing Protocol
- Initiation: 0.6 mg/day.
- Titration: +0.6 mg/wk up to 3.0 mg.
- Max dose: 3.0 mg/day (Saxenda®).
- Break between cycles: Gradual taper before discontinuation.
Washout & Cycle Restart
When can I restart?
Gradual taper before discontinuation.
Minimum wait period: 2 weeks
Storage Instructions
- Powder: 2–8 °C.
- Solution: 2–8 °C, use within 30 days.
Important Notes
- FDA-approved: Victoza® (T2D) and Saxenda® (obesity).
- Daily administration (unlike weekly semaglutide).
- Gradual titration is necessary.
- Check thyroid history (MTC/MEN2).
Potential Benefits & Side Effects
Potential Benefits:
- Proven weight loss (~8% in SCALE trials).
- Glycemic control in T2D.
- Cardiovascular benefits (LEADER trial).
- Flexible daily administration.
Potential Side Effects:
- Nausea (very common initially).
- Diarrhea, constipation.
- Headache.
- Rare: pancreatitis.
⚠️ Serious Warnings & Long-Term Risks
The following warnings are based on published literature, FDA labels, and post-marketing surveillance. They do not constitute medical advice. Consult a healthcare professional.
Thyroid C-cell tumors (medullary thyroid carcinoma)
In rodents, liraglutide caused dose-dependent thyroid C-cell tumors. Contraindicated in patients with personal/family history of MTC or MEN 2.
📄 FDA Boxed Warning — Saxenda® LabelAcute pancreatitis
Reports of acute pancreatitis in post-marketing surveillance. Discontinue if suspected.
📄 FDA Label — Victoza®Increased heart rate
Small increase in heart rate (2-3 bpm) observed in clinical trials. Monitor in patients with cardiac conditions.
📄 LEADER Trial — NEJM 2016References
- NEJM — SCALE — Liraglutide 3.0 mg for obesity
View Source - NEJM — LEADER — Liraglutide cardiovascular outcomes
View Source
Recommended Supplements
Vitamin B12 (Methylcobalamin)
Vitamin D3 + K2
Omega-3 Fish Oil (EPA/DHA)
Protein / Collagen
Fiber Supplement (Psyllium)
External Sources & Regulatory Status
Regulatory Approvals
Victoza® / Saxenda® · Type 2 diabetes / Obesity (2010)
Victoza® / Saxenda® · Type 2 diabetes / Obesity (2009)
Victoza® · Type 2 diabetes (2010)
Victoza® / Saxenda® · Type 2 diabetes / Obesity (2010)
FDA/EMA approved (Victoza®/Saxenda®)
Educational information. Not medical advice, and no efficacy claim is implied. Regulatory approval is not a use recommendation by AllPeptides.eu.
Continue Your Research
Explore tools and guides related to this protocol.
Important Disclaimer
The content of this website is provided exclusively for informational and educational purposes within the context of research literature.
Read the full Disclaimer →